Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Greg Guzauskas"'
Autor:
Michael Recht, Antony P. Martin, Eileen K. Sawyer, Nanxin Li, Marta T. Slomka, Jamie O'Hara, Konrad Maruszczyk, Mark Stevenson, Thomas W. Burke, Greg Guzauskas
Publikováno v:
Journal of Medical Economics. 24:363-372
Hemophilia B (HB) is a rare congenital disorder characterized by bleeding-related complications which are managed by prophylactic or post-bleeding event ("on-demand") replacement of clotting factor IX (FIX). The standard of care for severe HB is life
Autor:
Dina Hassen, Marc S. Williams, Jing Hao, David L. Veenstra, Greg Guzauskas, Susan R. Snyder, Josh F. Peterson
Publikováno v:
Genetics in Medicine. 21:2840-2841
Autor:
Matt Wasserman, Junfeng Yang, Greg Guzauskas, Yonghong Yang, Kunling Shen, Bruce C. M. Wang, Betsy Hilton, Raymond Farkouh, D Liu
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 7, p e0201245 (2018)
PLoS ONE, Vol 13, Iss 7, p e0201245 (2018)
Background The burden of pneumococcal disease in China is high, and a 13-valent pneumococcal conjugate vaccine (PCV13) recently received regulatory approval and is available to Chinese infants. PCV13 protects against the most prevalent serotypes caus
Autor:
Fuki M. Hisama, Brian H. Shirts, William M. Grady, Wylie Burke, Colin C. Pritchard, David L. Veenstra, Carlos J. Gallego, Greg Guzauskas, Caroline S. Bennette, Martha Horike-Pyne, Laura M. Amendola, Gail P. Jarvik
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(18)
Purpose To evaluate the cost effectiveness of next-generation sequencing (NGS) panels for the diagnosis of colorectal cancer and polyposis (CRCP) syndromes in patients referred to cancer genetics clinics. Patients and Methods We developed a decision
Publikováno v:
Cancer Research. 77:CT160-CT160
Background: Glioblastoma is the most common and aggressive primary brain tumor. Survival times for GBM have improved significantly since 2005. Researchers in 2005 demonstrated that adding TMZ, an oral alkylating agent, to surgery and radiation extend
Publikováno v:
Annals of emergency medicine. 61(1)
Study objective The European Cooperative Acute Stroke Study III (ECASS III) showed that recombinant tissue plasminogen activator (rtPA) administered 3 to 4.5 hours after acute ischemic stroke led to improvement in patient disability versus placebo. W
Autor:
Stephanie M. Fullerton, Greg Guzauskas, Dena Freeman, Nicholas R. Anderson, Kelly Fryer-Edwards
Advances in clinical translational research have led to an explosion of interest in infrastructure development and data sharing facilitated by biorepositories of specimens and linked health information. These efforts are qualitatively different from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c3cb744946c03cb4f622375b84a597
https://europepmc.org/articles/PMC3038212/
https://europepmc.org/articles/PMC3038212/